Following the report that PDGFB is one of the mTOR signalling pathway agonists [36], we previously showed that supplementing the KLF6-targeted ccRCC cells with recombinant human PDGFB re-activated the impaired mTORC1 activity in these cells [32]. Here, PDGFB is linked to nonpapillary renal cell carcinoma.